Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Updates in the management of pancreatic cancer from ASCO 2019

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.06.19
Views: 2124

Dr Ian Chau, Prof Michel Ducreux and Dr Vaihab Sahai

Dr Ian Chau (The Royal Marsden Hospital, London, UK), Prof Michel Ducreux (Institut Gustave Roussy, Paris, France), Dr Vaihab Sahai (University of Michigan, Michigan, USA) discuss the latest updates from ASCO 2019 for the management of patients with pancreatic cancer.

The discussion starts with an overview of the current clinical landscape for patients with operable pancreatic cancer and Professor Ducreux summarises the results of the APACT study presented in Chicago. The panel go on to discuss recent updates from trials in the neo-adjuvant setting for this patient population including the ongoing ALLIANCE trial. The panel then debate the role of radiotherapy in the operable patient setting.

The discussion goes on to cover the current NCCN and ASCO guidelines for the management of patients with metastatic pancreatic cancer. Dr Sahai provides an overview of the POLO study data presented at ASCO 2019 and highlights what these results mean for clinical practice.

The session concludes with the experts discussing the importance of genetic testing and genetic counselling for patients and their families and they share their view on the future of personalised medicine in pancreatic cancer.

Current management of resectable pancreatic cancer
Results and clinical impact of the APACT trial
Implications of neoadjuvant treatment strategies
Role of radiotherapy in the pre- and post-operative settings
Treatment recommendations for patients with metastatic pancreatic cancer
Current NCCN and ASCO guidelines for pancreatic cancer treatment
Results from the POLO trial and its clinical significance
Using genetic testing to personalise therapy

This programme has been supported by an unrestricted educational grant from AstraZeneca.


· ASCO 2019

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation